Neumora Therapeutics is trading 6.25% higher at $0.50, alongside improving U.S. technology sentiment; no company-specific catalyst has been established. - The Nasdaq rebound may be supporting the gain, but available evidence does not establish a company-specific cause. - A market listing showed no company headlines for October 19.